Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | PTGFR | P43088 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464727 | 0.93 | DHODH (0.71) | DHODHTSHRPDE10APTGFR | |
| SCHEMBL2372696 | 0.89 | DHODH (0.48) | DHODHPTGFRALDH1A1SMN1; SMN2 | |
| SCHEMBL2372855 | 0.86 | DHODH (0.71) | DHODHTSHRPDE10APTGFR | |
| SCHEMBL2373037 | 0.85 | DHODH (0.70) | DHODHTSHRPDE10ASMN1; SMN2 | |
| SCHEMBL2371929 | 0.85 | DHODH (0.61) | DHODHTSHRPDE10APTGFRALDH1A1 | |
| SCHEMBL2373344 | 0.83 | DHODH (0.82) | DHODHTSHRPDE10APTGFR | |
| SCHEMBL2373290 | 0.83 | DHODH (0.59) | DHODHTSHRPDE10APTGFRALDH1A1 | |
| SCHEMBL2462805 | 0.83 | DHODH (0.57) | DHODHPTGFRALDH1A1SMN1; SMN2 | |
| SCHEMBL2373336 | 0.81 | DHODH (0.62) | DHODHTSHRPDE10APTGFR | |
| SCHEMBL2372758 | 0.81 | DHODH (0.56) | DHODHTSHRPDE10APTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549872-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8658636-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2549872-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130012499-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119701-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012499-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV5 | DHODH 2190/4885TSHR 2692/4885PDE10A 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.